Taok1 Mouse shRNA Lentiviral Particle (Locus ID 216965)

CAT#: TL519661V

Taok1 - Mouse shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml.

Product Images

GFP signal was observed under microscope at 48 hours after transduction of TL519661B virus into HEK293 cells. TL519661B virus was prepared using lenti-shRNA TL519661B and TR30037 packaging kit.

• 

  GFP signal was observed under microscope at 48 hours after transduction of [TL519661C] virus into HEK293 cells. [TL519661C] virus was prepared using lenti-shRNA [TL519661C] and TR30037 packaging kit.

• 

  GFP signal was observed under microscope at 48 hours after transduction of [TL519661D] virus into HEK293 cells. [TL519661D] virus was prepared using lenti-shRNA [TL519661D] and TR30037 packaging kit.

Specifications

Product Data

• Locus ID: 216965
• Synonyms: 2810468K05Rik; AU020252; D130018F14Rik; Map3k16; Markk; mKIAA1361; Psk2
• Vector: pGFP-C-shLenti
• Format: Lentiviral particles
• RefSeq: NM_144825, NM_144825.1, NM_144825.2, BC151012, BC016522, BC019960, BC034906, BC047271, BC092076, BC151015, BC151016, BC156277, BC172656, NM_001364133, NM_001364134, NM_144825.3
• UniProt ID: Q5F2E8
• Summary: Serine/threonine-protein kinase involved in various processes such as p38/MAPK14 stress-activated MAPK cascade, DNA damage response and regulation of cytoskeleton stability. Phosphorylates MAP2K3, MAP2K6 and MARK2. Acts as an activator of the p38/MAPK14 stress-activated MAPK cascade by mediating phosphorylation and subsequent activation of the upstream MAP2K3 and MAP2K6 kinases. Involved in G-protein coupled receptor signaling to p38/MAPK14. In response to DNA damage, involved in the G2/M transition DNA damage checkpoint by activating the p38/MAPK14 stress-activated MAPK cascade, probably by mediating phosphorylation of MAP2K3 and MAP2K6. Acts as a regulator of cytoskeleton stability by phosphorylating 'Thr-208' of MARK2, leading to activate MARK2 kinase activity and subsequent phosphorylation and detachment of MAPT/TAU from microtubules. Also acts as a regulator of apoptosis: regulates apoptotic morphological changes, including cell contraction, membrane blebbing and apoptotic bodies formation via activation of the MAPK8/JNK cascade (By similarity).[UniProtKB/Swiss-Prot Function]
• shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service.
• Performance Guaranteed: OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.
  
  For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).